Nanyang Biologics
Singapore, Singapore· Est.
AI‑powered biotech turning nature’s molecular intelligence into longevity therapeutics and nutraceuticals.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered biotech turning nature’s molecular intelligence into longevity therapeutics and nutraceuticals.
Metabolic HealthInflammationOncology
Technology Platform
A proprietary AI‑led platform that integrates biological, chemical, and botanical data to predict bioactive natural compounds and accelerate early‑stage drug discovery.
Opportunities
Leveraging AI to unlock nature‑derived therapeutics positions NYB to capture emerging longevity and wellness markets, while strategic collaborations could accelerate IND filing and commercialization.
Risk Factors
Early‑stage discovery uncertainty, regulatory challenges for novel natural‑product drugs, and competition from larger AI‑driven biotech firms could impede progress.
Competitive Landscape
NYB competes with AI‑enabled biotech startups and traditional natural‑product companies, differentiating through its integrated AI‑botanical platform and longevity‑focused therapeutic agenda.